

# Emanuela Ricciotti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5732066/emanuela-ricciotti-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46  
papers

4,806  
citations

27  
h-index

50  
g-index

50  
ext. papers

5,785  
ext. citations

10  
avg, IF

5.89  
L-index

#	Paper	IF	Citations
46	Aspirin in Hepatocellular Carcinoma. <i>Cancer Research</i> , <b>2021</b> , 81, 3751-3761	10.1	3
45	Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. <i>Advances in Biological Regulation</i> , <b>2021</b> , 81, 100818	6.2	3
44	Aspirin in the Prevention of Cardiovascular Disease and Cancer. <i>Annual Review of Medicine</i> , <b>2021</b> , 72, 473-495	17.4	3
43	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic.. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 751451	6	1
42	Pharmacological Characterization of the Microsomal Prostaglandin E Synthase-1 Inhibitor AF3485 and. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 374	5.6	5
41	Druggable Prostanoid Pathway. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1274, 29-54	3.6	5
40	LDL-mimetic lipid nanoparticles prepared by surface KAT ligation for MRI of atherosclerosis. <i>Chemical Science</i> , <b>2020</b> , 11, 11998-12008	9.4	5
39	NSAID-Gut Microbiota Interactions. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 1153	5.6	24
38	Modulation of Apoptotic Cell Death and Neuroprotective Effects of Glutathione-L-Dopa Codrug Against HO-Induced Cellular Toxicity. <i>Antioxidants</i> , <b>2019</b> , 8,	7.1	3
37	Comparative evaluation of RNA-Seq library preparation methods for strand-specificity and low input. <i>Scientific Reports</i> , <b>2019</b> , 9, 13477	4.9	14
36	Prostaglandin regulation of T cell biology. <i>Pharmacological Research</i> , <b>2019</b> , 149, 104456	10.2	5
35	Fatty acid transport protein $\beta$ reprograms neutrophils in cancer. <i>Nature</i> , <b>2019</b> , 569, 73-78	50.4	215
34	Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 370, 416-426	4.7	9
33	Distinct vascular genomic response of proton and gamma radiation-A pilot investigation. <i>PLoS ONE</i> , <b>2019</b> , 14, e0207503	3.7	4
32	Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs. <i>Circulation</i> , <b>2018</b> , 138, 2367-2378	16.7	9
31	Lipocalin-Like Prostaglandin D Synthase but Not Hemopoietic Prostaglandin D Synthase Deletion Causes Hypertension and Accelerates Thrombogenesis in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2018</b> , 367, 425-432	4.7	19
30	COX-2 mediates pro-tumorigenic effects of PKC $\beta$ in prostate cancer. <i>Oncogene</i> , <b>2018</b> , 37, 4735-4749	9.2	28

29	The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. <i>Trends in Pharmacological Sciences</i> , <b>2017</b> , 38, 733-748	13.2	74
28	A comparison of Illumina and Ion Torrent sequencing platforms in the context of differential gene expression. <i>BMC Genomics</i> , <b>2017</b> , 18, 602	4.5	38
27	Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 2407-2417	15.9	90
26	A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	27
25	Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. <i>Oncotarget</i> , <b>2016</b> , 7, 32462-77	3.3	101
24	Understanding multicellular function and disease with human tissue-specific networks. <i>Nature Genetics</i> , <b>2015</b> , 47, 569-76	36.3	473
23	Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury. <i>Circulation Research</i> , <b>2013</b> , 112, 432-40	15.7	10
22	COX-2, the dominant source of prostacyclin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, E183	11.5	34
21	Functionalized low-density lipoprotein nanoparticles for in vivo enhancement of atherosclerosis on magnetic resonance images. <i>Bioconjugate Chemistry</i> , <b>2012</b> , 23, 2313-9	6.3	12
20	Mechanistic and pharmacological issues of aspirin as an anticancer agent. <i>Pharmaceuticals</i> , <b>2012</b> , 5, 1346-71	5.2	49
19	Vascular COX-2 modulates blood pressure and thrombosis in mice. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 132ra54	17.5	164
18	Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 6727-32	11.5	39
17	Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2012</b> , 341, 242-50	4.7	27
16	Niacin and biosynthesis of PGD <sub>2</sub> by platelet COX-1 in mice and humans. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 1459-68	15.9	46
15	Prostaglandins and inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 986-1000	9.4	2030
14	NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes. <i>Journal of Immunology</i> , <b>2010</b> , 184, 2140-7	5.3	19
13	Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. <i>Circulation</i> , <b>2010</b> , 121, 2654-60	16.7	45
12	Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 974-81	6	47

11	Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 7548-52	11.5	95
10	Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 1179-88	5.4	66
9	Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. <i>Circulation</i> , <b>2008</b> , 117, 1302-9	16.7	106
8	Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 14507-12	11.5	162
7	De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. <i>Circulation Research</i> , <b>2006</b> , 98, 593-5	15.7	108
6	Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. <i>Blood</i> , <b>2006</b> , 107, 3572-4	2.2	34
5	Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 115-25	6.1	25
4	Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 1295-301	15.1	225
3	Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. <i>Circulation</i> , <b>2004</b> , 109, 1468-71	16.7	195
2	Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. <i>British Journal of Pharmacology</i> , <b>2003</b> , 138, 634-41	8.6	37
1	The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. <i>Current Medical Research and Opinion</i> , <b>2002</b> , 18, 503-11	2.5	72